TY - JOUR T1 - Canadian Rheumatology Association Recommendations for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis JF - The Journal of Rheumatology JO - J Rheumatol SP - 390 LP - 399 DO - 10.3899/jrheum.220261 VL - 50 IS - 3 AU - Roberta Berard AU - Hon Yan Ng AU - Andrea Human AU - David Piskin AU - Muhammed Dhalla AU - Chloe Gottlieb AU - Michelle Batthish AU - Gaëlle Chédeville AU - Christina Forest AU - Eric Fortin AU - Jane Gardiner AU - Kerstin Gerhold AU - Andre Jastrzebski AU - Bianca Lang AU - Paivi M.H. Miettunen AU - Sabrina Morgenstern AU - Marie-Paule Morin AU - Alan Rosenberg AU - Dax G. Rumsey AU - Carlos E. Solarte AU - Nasrin Tehrani AU - Karen Watanabe Duffy AU - Jordi Pardo Pardo AU - Glen S. Hazlewood AU - Deborah M. Levy Y1 - 2023/03/01 UR - http://www.jrheum.org/content/50/3/390.abstract N2 - Objective To develop Canadian recommendations for the screening, monitoring, and treatment of uveitis associated with juvenile idiopathic arthritis (JIA).Methods Recommendations were developed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE)-ADOLOPMENT approach. A working group of 14 pediatric rheumatologists, 6 ophthalmologists, 2 methodologists, and 3 caregiver/patient representatives reviewed recent American College of Rheumatology (ACR)/Arthritis Foundation (AF) recommendations and worked in pairs to develop evidence-to-decision (EtD) tables. A survey to assess agreement and recommendations requiring group discussion was completed. EtD tables were presented, discussed, and voted upon at a virtual meeting, to produce the final recommendations. A health equity framework was applied to all aspects of the adolopment process including the EtD tables, survey responses, and virtual meeting discussion.Results The survey identified that 7 of the 19 recommendations required rigorous discussion. Seventy-five percent of working group members attended the virtual meeting to discuss controversial topics as they pertained to the Canadian environment, including timing to first eye exam, frequency of screening, escalation criteria for systemic and biologic therapy, and the role of nonbiologic therapies. Equity issues related to access to care and advanced therapeutics across Canadian provinces and territories were highlighted. Following the virtual meeting, 5 recommendations were adapted, 2 recommendations were removed, and 1 was developed de novo.Conclusion Recommendations for JIA-associated uveitis were adapted to the Canadian context by a working group of pediatric rheumatologists, ophthalmologists with expertise in the management of uveitis, and parent/patient input, taking into consideration cost, equity, and access. ER -